| Literature DB >> 20180063 |
Abstract
Systemic treatment of advanced prostate cancer is multifaceted. First-line therapy is antihormonal treatment with androgen deprivation or antiandrogens. Chemotherapy is effective in hormone refractory (castration resistant) prostate cancer. Alternative and supplementary options include radionuclides, steroids, and symptomatic measures. Use of bisphosphonates is standard in metastatic bone disease. Treatment of patients with metastatic prostate cancer is palliative. The aims are prolongation of overall survival, prolongation of progression-free survival, control and relief of symptoms, and restoration and maintenance of quality of life. Current options allow personalized patient care. New approaches and new drugs will increase the therapeutic possibilities considerably.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20180063 DOI: 10.1007/s00120-010-2238-3
Source DB: PubMed Journal: Urologe A ISSN: 0340-2592 Impact factor: 0.639